8-K: Surmodics Merger Faces Second Request from FTC, Delaying Closing Timeline

Surmodics and its merger partner received a second request for information from the Federal Trade Commission, extending the waiting period for their proposed merger.

Summary

• Surmodics, Inc. is undergoing a merger with BCE Parent, LLC, and BCE Merger Sub, Inc.
• On August 12, 2024, both Surmodics and an affiliate of BCE Parent received a second request for additional information from the Federal Trade Commission (FTC).
• This second request extends the waiting period required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 until 30 days after the parties substantially comply with the request, unless the FTC terminates it sooner.
• The companies are cooperating with the FTC to expedite the process.
• The merger is still expected to close before the outside date of February 28, 2025, subject to potential extensions.

Sentiment

Score: 4

Explanation: The document indicates a delay in the merger process due to regulatory hurdles, which is a negative development. However, the companies are cooperating, and the merger is still expected to close, preventing a more negative score.

Positives

• Both Surmodics and Parent are cooperating with the FTC to expedite the merger process.
• The companies still expect to complete the merger before the outside date of February 28, 2025.

Negatives

• The second request from the FTC has introduced a delay in the merger timeline.
• There is a risk that the merger may not be completed within the anticipated timeframe or at all.
• The company may be required to pay a termination fee of $20,380,000 if the merger is terminated under certain conditions.
• The announcement and pendency of the merger may negatively impact the company's business, operating results, and stock price.

Risks

• The merger may not be consummated within the anticipated time period, or at all.
• The parties may fail to obtain shareholder approval of the Merger Agreement.
• The parties may fail to secure the termination or expiration of any waiting period applicable under the HSR Act.
• Other conditions to the consummation of the Merger under the Merger Agreement may not be satisfied.
• All or part of Parent's financing may not become available.
• The significant limitations on remedies contained in the Merger Agreement may limit or entirely prevent the Company from specifically enforcing Parent's obligations under the Merger Agreement or recovering damages for any breach by Parent.
• The company's stock price may decline significantly if the merger is not completed.
• The merger agreement may be terminated in circumstances requiring the company to pay Parent a termination fee of $20,380,000.
• The circumstances of the termination, including the possible imposition of a 12-month tail period during which the termination fee could be payable upon certain subsequent transactions, may have a chilling effect on alternatives to the merger.
• The company's business, operating results, or stock price may suffer due to the announcement or pendency of the merger.
• The company's current plans and operations may be disrupted.
• The company's ability to retain or recruit key employees may be adversely affected.
• The company's business relationships may be adversely affected.
• The company's management's or employees' attention may be diverted from other important matters.
• The merger and related transactions may involve unexpected costs, liabilities, or delays.
• There are other economic, business, competitive, legal, regulatory, and/or tax factors that could impact the merger.

Future Outlook

The merger is still expected to close before the outside date of February 28, 2025, subject to potential extensions. The companies are cooperating with the FTC to expedite the process.

Management Comments

• The Company and Parent are in the process of gathering information and documentary materials responsive to the Second Request and intend to continue to cooperate with the FTC in an effort to obtain expiration or termination of the HSR Act waiting period for the Merger as expeditiously as possible.

Industry Context

The request for additional information from the FTC is not uncommon in large mergers and acquisitions, particularly in industries with potential antitrust concerns. This indicates that the regulatory bodies are scrutinizing the deal to ensure fair competition.

Comparison to Industry Standards

• Merger reviews by the FTC are a standard part of the process for large transactions, similar to the reviews seen in other major deals in the medical device and technology sectors.
• The second request for information is not unusual and has been seen in other mergers such as the acquisition of Medtronic by Covidien, where regulatory scrutiny led to delays and divestitures.
• The 30-day waiting period extension is also a common occurrence, similar to the review periods in the acquisition of Allergan by AbbVie, where the FTC requested additional information.

Stakeholder Impact

• Shareholders may experience uncertainty due to the delay in the merger.
• Employees may be concerned about the potential impact of the merger on their jobs.
• Customers and suppliers may experience disruptions due to the ongoing merger process.

Next Steps

• Surmodics and Parent will continue to gather information and documentary materials responsive to the Second Request.
• The companies will cooperate with the FTC to obtain expiration or termination of the HSR Act waiting period.
• The companies will work towards satisfying the remaining closing conditions for the merger.

Key Dates

Keywords

merger, FTC, HSR Act, antitrust, Surmodics, BCE Parent, acquisition, regulatory, waiting period, delay